Edition:
United States

Vernalis PLC (VER.L)

VER.L on London Stock Exchange

25.00GBp
24 Mar 2017
Change (% chg)

0.12 (+0.50%)
Prev Close
24.88
Open
25.00
Day's High
25.00
Day's Low
24.75
Volume
93,904
Avg. Vol
359,309
52-wk High
53.75
52-wk Low
23.00

Latest Key Developments (Source: Significant Developments)

Vernalis Plc enters drug discovery collaboration with Servier
Monday, 6 Mar 2017 02:10am EST 

Vernalis Plc : New drug discovery collaboration with servier .Will receive EUR 2 million upfront payment, fees, research milestones and share in downstream success of any products out of collaboration.  Full Article

Vernalis says U.S. FDA accepts CCP-08 new drug application for full review
Wednesday, 21 Dec 2016 02:13am EST 

Vernalis Plc : FDA accepts CCP-08 NDA for full review .Triggers a milestone payment from Vernalis to Tris.  Full Article

Vernalis says cash position ahead of market expectations
Thursday, 7 Jul 2016 08:47am EDT 

Vernalis Plc : Company's unaudited cash position (including cash and cash equivalents and held to maturity assets), at June 30, was 84 mln stg . Cash position is ahead of market expectations and reflects favourable impact of recent strengthening of U.S. dollar since UK referendum vote .At year-end 73 pct of company's cash was held in U.S. dollars.  Full Article

Vernalis PLC says FDA approves NDA for Tuzistra XR
Friday, 1 May 2015 02:00am EDT 

Vernalis PLC and Tris Pharma:Receive FDA approval of NDA for Tuzistra XR (codeine polistirex and chlorpheniramine polistirex).  Full Article

Vernalis enters into research collaboration with Taisho Pharmaceutical Co., Ltd
Tuesday, 7 Apr 2015 02:00am EDT 

Vernalis PLC:Enters into a drug discovery collaboration with Taisho Pharmaceutical Co., Ltd., utilizing Vernalis' fragment and structure-based drug discovery platform against an undisclosed target for the development of potential antibiotic agents.Financial terms of this collaboration are not disclosed.  Full Article

More From Around the Web

BRIEF-Vernalis Plc enters drug discovery collaboration with Servier

* Will receive EUR 2 million upfront payment, fees, research milestones and share in downstream success of any products out of collaboration Source text for Eikon: Further company coverage: